EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

Identification of Active Compounds of Centipeda minima for Potentiating Tumor Immunotherapy in Non‐Small Cell Lung Cancer via FANCD2 ‐ cGAS / STING / IFN ‐I Signaling Axis

Han-Chen Wang iD, Chu-Ying Chen iD, Jiang-Tao Xiao iD, Rou-Qiao Zheng, Wen-Da He, Zi-Wei Xu, Su-Fen Wei, Tao Su iD, Guang-Biao Zhou iD, Yong-Qiang Liu iD

Phytotherapy Research · 2026-11 · 40 (11) · 6791-6808

DOI: 10.1002/ptr.70460 ↗

At a glance

Journal article in Phytotherapy Research, published online on 2026-09-24. Written by Han-Chen Wang and 9 co-authors. Institution: Key Laboratory of Chinese Medicinal Resource From Lingnan, Ministry of Education, School of Pharmaceutical Sciences, Guangzhou University of Chinese …. Major MEDLINE topics: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Plant Extracts, Asteraceae. 41 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Key Research and Development Program of China, Guangdong Province Modern Agricultural Industrial Technology System Innovation Team Construction Project, National Natural Science Foundation of China.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Activation of cGAS/STING/IFN‐I signaling pathway serves as a potential therapeutic strategy to enhance CD8 + T cells infiltration and augment antitumor immunotherapy. The medicinal herb Centipeda minima has been traditionally employed to treat respiratory diseases and cancer; however, whether C. minima and its bioactive constituents can activate CD8 + T cell‐mediated antitumor immunity in non‐small cell lung cancer (NSCLC) remains elusive. In this study, the ethanol extract of C. minima (ECM) significantly enhanced the cytotoxic activity of human peripheral blood mononuclear cell‐derived activated T cells and murine primary CD8 + T cells against NSCLC cells, and promoted CD8 + T cell infiltration in the LLC syngeneic tumor model. RNA‐seq profiling indicated that ECM potentially triggers type‐I interferon (IFN‐I)‐mediated innate immunity in NSCLC. Mechanistically, ECM treatment activated the cGAS/STING pathway in NSCLC cells, as evidenced by increased phosphorylation of TBK1 and IRF3, elevated IFN‐I gene expression, and enhanced CD8 + T cells activity. Notably, ECM markedly downregulated both mitochondrial and nuclear FANCD2 protein levels, which may facilitate cytosolic release of mitochondrial and nuclear DNA, thereby stimulating the cGAS/STING/IFN‐I signaling axis. ECM‐induced FANCD2 downregulation was markedly reversed by the proteasome inhibitor MG‐132. Combination treatment with ECM and anti‐PD‐1 antibody synergistically suppressed tumor growth in the LLC syngeneic model, accompanied by elevated IFN‐I expression and pronounced recruitment of activated CD8 + T cells. Moreover, 3‐ O ‐methylquercetin and several sesquiterpene lactones abundant in ECM were identified to downregulate FANCD2, activate TBK1/IRF3 pathway, and enhance IFN‐I expression in NSCLC cells. Among these active compounds, arnicolide D promoted FANCD2 degradation in a proteasome‐dependent manner, whereas 3‐ O ‐methylquercetin predominantly suppressed FANCD2 gene expression. Collectively, our findings suggest that FANCD2 may serve as a novel therapeutic target for enhancing antitumor innate immunity, and that C. minima along with its active compounds can potentiate antitumor immunotherapy by activating the FANCD2‐cGAS/STING/IFN‐I signaling axis.

Subjects

MeSH terms (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsPlant ExtractsAsteraceaeHumansAnimalsSTING ProteinImmunotherapycGAS-STING Signaling PathwaySignal TransductionMiceMembrane ProteinsCD8-Positive T-LymphocytesNucleotidyltransferasesInterferon Type ICyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseFanconi Anemia Complementation Group D2 ProteinCell Line, TumorInterferon Regulatory Factor-3Mice, Inbred C57BLProtein Serine-Threonine Kinases

Author keywords

3‐O‐methylquercetinFANCD2immunotherapythe ethanol extract of C. minimatype‐I interferons

Substances

STING ProteinSTING1 protein, humanPlant ExtractsMembrane ProteinsNucleotidyltransferasesInterferon Type ICyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseFanconi Anemia Complementation Group D2 ProteincGAS protein, humanInterferon Regulatory Factor-3

Authors and institutions

  • Key Laboratory of Chinese Medicinal Resource From Lingnan, Ministry of Education, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Research Center of Chinese Herbal Resource Science and Engineering, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Department of Gastroenterology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangdong Provincial Academy of Chinese Medical Sciences, G…
  • Institute of Cancer Research, Henan Academy of Innovations in Medical Sciences, Zhengzhou, China.
  • Key Laboratory of Chronic Disease Prevention and Control of Traditional Chinese Medicine of Guangdong Higher Education Institutes, Guangzhou University of Chinese Medicine, KLGHEI (2024KSYS024), Guangzhou, China.

ORCID profiles: Han-Chen Wang, Chu-Ying Chen, Jiang-Tao Xiao, Tao Su, Guang-Biao Zhou, Yong-Qiang Liu

Funding

  • National Key Research and Development Program of China
  • Guangdong Province Modern Agricultural Industrial Technology System Innovation Team Construction Project
  • National Natural Science Foundation of China
  • Guangdong Provincial Key Laboratory of Chinese Medicine for Prevention and Treatment of Refractory Chronic Diseases
  • First-Class Discipline Capacity Enhancement Program of Guangzhou University of Chinese Medicine

Cite

APA

Wang, H. C., Chen, C. Y., Xiao, J. T., Zheng, R. Q., He, W. D., Xu, Z. W., Wei, S. F., Su, T., Zhou, G. B., & Liu, Y. Q. (2026). Identification of Active Compounds of Centipeda minima for Potentiating Tumor Immunotherapy in Non‐Small Cell Lung Cancer via FANCD2 ‐ cGAS / STING / IFN ‐I Signaling Axis. Phytotherapy Research, 40(11), 6791-6808. https://doi.org/10.1002/ptr.70460

Vancouver

Wang HC, Chen CY, Xiao JT, Zheng RQ, He WD, Xu ZW, et al. Identification of Active Compounds of Centipeda minima for Potentiating Tumor Immunotherapy in Non‐Small Cell Lung Cancer via FANCD2 ‐ cGAS / STING / IFN ‐I Signaling Axis. Phytotherapy Research. 2026;40(11):6791-6808. doi:10.1002/ptr.70460

BibTeX
@article{Wang2026,
  author = {Wang, Han-Chen and Chen, Chu-Ying and Xiao, Jiang-Tao and Zheng, Rou-Qiao and He, Wen-Da and Xu, Zi-Wei and Wei, Su-Fen and Su, Tao and Zhou, Guang-Biao and Liu, Yong-Qiang},
  title = {Identification of Active Compounds of Centipeda minima for Potentiating Tumor Immunotherapy in Non‐Small Cell Lung Cancer via FANCD2 ‐ cGAS / STING / IFN ‐I Signaling Axis},
  journal = {Phytotherapy Research},
  year = {2026},
  volume = {40},
  number = {11},
  pages = {6791--6808},
  doi = {10.1002/ptr.70460}
}
Start for free →